Qiagen

Verogen is an independent forensic genomics company that tailors next-generation sequencing solutions for forensic laboratories.

BLIRT develops, manufactures, and commercializes standardized and customized solutions for proteins and enzymes as well as molecular biology reagents. Its offering includes proteins and enzymes that are critical to the life sciences industry and diagnostic kit manufacturers.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Actome focuses on developing emulsion coupling technology for life science research and personalized medicine.

Verogen is an independent forensic genomics company that tailors next-generation sequencing solutions for forensic laboratories.

NeuMoDx Molecular, Inc. is a molecular diagnostics company based in Ann Arbor, Michigan, founded in 2012. It specializes in developing solutions for molecular diagnostic testing in hospital and clinical reference laboratories. The company’s platform provides in-vitro testing tools that enhance the efficiency and cost-effectiveness of laboratory operations. By improving the capabilities of laboratory professionals, NeuMoDx aims to increase the adoption of molecular diagnostic testing among medical providers, facilitating earlier and more accurate disease identification and treatment. In 2013, NeuMoDx changed its name from Molecular Systems Corporation and has since become a subsidiary of QIAGEN N.V.

N-of-One Therapeutics provides cancer care services. Its team of clinicians and scientists works with a network of diagnostic laboratories, research institutions, and cancer experts to provide access to cancer research, medical science, and molecular diagnostic testing. The company conducts research to assess the standard of care and other diagnostic and treatment opportunities for various cancer types.

Parsagen Diagnostics is comprised of a team of passionate and driven leaders who have a proven ability to bring a product from conception through commercialization in multiple global markets. As they expand their presence in the US & abroad, they are looking for people who exhibit flexibility under pressure, who have a proclivity to seek & approach challenges with optimism and grit, and who can identify areas of need and contribute to their ultimate fulfillment.

ArcherDX, Inc. is a genomics company based in Boulder, Colorado, specializing in the development and commercialization of advanced molecular pathology products and services. The company focuses on next-generation sequencing technologies to enhance genetic mutation detection, offering a range of research products such as VariantPlex, FusionPlex, LiquidPlex, and Immunoverse. ArcherDX's proprietary Anchored Multiplexed PCR (AMP™) chemistry, combined with powerful bioinformatics software, allows for efficient identification of genetic mutations, including gene fusions and point mutations. The company also provides customization services for clinical and biopharmaceutical customers through its assay designer platform, enabling the development of personalized applications. Its products are primarily aimed at academic and reference laboratories, biopharmaceutical firms, and contract research organizations, supporting therapy optimization and cancer monitoring. Founded in 2013, ArcherDX operates as a subsidiary of Invitae Corporation.

STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.

OmicSoft is recognized for its suite of cutting-edge software solutions that enable scientists and researchers to efficiently analyze and visualize their own data sets and compare them to massive volumes of publicly available ‘omics’ data sets – such as The Cancer Genome Atlas (TCGA) operated by the U.S. National Cancer Institute – and share results with colleagues. These solutions, which integrate enterprise access and cloud-based resources, are essential in addressing the rapidly growing need of researchers in discovery and translational research to manage, compare and share the massive volumes of data on DNA, RNA and other biological variables generated with next-generation sequencing (NGS) technologies.

Exosome Diagnostics, Inc. specializes in the development and commercialization of biofluid-based molecular diagnostic tests aimed at enhancing personalized precision healthcare. The company employs a proprietary exosome technology platform that extracts and analyzes molecular information from exosomes present in various biofluids, including blood, urine, and cerebrospinal fluid. This approach enables non-invasive diagnostics for serious diseases, significantly reducing the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously analyzes exosomal RNA and circulating tumor DNA in a single assay to identify actionable mutations across multiple cancer types. By combining RNA, DNA, and protein analysis, Exosome Diagnostics provides comprehensive molecular insights that can transform the detection, diagnosis, treatment, and monitoring of cancer and other serious conditions. The company also collaborates with pharmaceutical firms to enhance research and development processes, including biomarker discovery and the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, Exosome Diagnostics operates as a subsidiary of Bio-Techne Corporation.

MO BIO Laboratories, Inc., founded in 1993 and based in Carlsbad, California, specializes in biotechnology research products, focusing on DNA and RNA isolation, protein extraction, and nucleic acid purification. The company develops and manufactures a range of products for life science research, including kits for soil, stool, and microbial nucleic acid purification. Additionally, MO BIO Laboratories provides sterility assurance services and certifications for various plastic and medical device suppliers, as well as for water and food quality. Its products are distributed both in the United States and internationally, with an online sales presence. As of 2015, MO BIO Laboratories operates as a subsidiary of Qiagen NV.

Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

BIOBASE is a provider of expert-curated biological databases, software and services for the life sciences.

Exosome Diagnostics, Inc. specializes in the development and commercialization of biofluid-based molecular diagnostic tests aimed at enhancing personalized precision healthcare. The company employs a proprietary exosome technology platform that extracts and analyzes molecular information from exosomes present in various biofluids, including blood, urine, and cerebrospinal fluid. This approach enables non-invasive diagnostics for serious diseases, significantly reducing the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously analyzes exosomal RNA and circulating tumor DNA in a single assay to identify actionable mutations across multiple cancer types. By combining RNA, DNA, and protein analysis, Exosome Diagnostics provides comprehensive molecular insights that can transform the detection, diagnosis, treatment, and monitoring of cancer and other serious conditions. The company also collaborates with pharmaceutical firms to enhance research and development processes, including biomarker discovery and the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, Exosome Diagnostics operates as a subsidiary of Bio-Techne Corporation.

CLC bio is a prominent provider of bioinformatics solutions, specializing in the analysis of genomic data derived from various high-throughput sequencing technologies. The company develops and sells enterprise software designed for both next-generation sequencing platforms and Sanger-based sequencing systems. By focusing on the needs of researchers and organizations in the life sciences, CLC bio enables users to efficiently interpret complex biological data, thus facilitating advancements in genomics and personalized medicine.

Ingenuity Systems is a developer of a software platform designed to support life science researchers by facilitating access to critical information. The platform enables enterprise customers to provide their researchers with resources through internal portals, search engines, and various software and workflow sources. This functionality allows researchers to effectively search, explore, visualize, and analyze biological and chemical data pertaining to genes, proteins, and small molecules, thereby enhancing their research capabilities and productivity in the life sciences field.

Drug Response Dx, headquartered in Hennigsdorf, Germany, was founded in February 2012 by a team of experts including Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner, and Dr. Joachim Rautter. The company specializes in developing biomarker tests specifically designed to evaluate treatment outcomes for rheumatoid arthritis. Their tests utilize a protein that predicts the individual effectiveness of TNF-alpha inhibitors, allowing for personalized treatment planning prior to medication administration. This approach facilitates timely initiation of treatment and increases the likelihood of positive patient outcomes. The company's biomarker set is prevalidated, and they have established proof of concept using serum samples from rheumatoid arthritis patients.

Intelligent Bio-Systems was founded in 2005 by Drs. Steven J. Gordon and Jingyue Ju to commercialize an advanced DNA sequencing system. Dr. Gordon previously founded Intelligent Automation Systems, which was responsible for a number of key instrumentation solutions which helped to complete the Human Genome Project. Dr. Ju is one of the key inventors of fluorescent energy transfer dyes used in most electrophoresis-based sequencers.

AmniSure is a diagnostic test for ROM cleared by the FDA for marketing and is reimbursable under most U.S. state Medicaid plans. The product is also approved in other markets around the world. The AmniSure test is a one-step, minimally invasive test strip using proprietary technology to detect tiny quantities of amniotic fluid in vaginal discharge. Results are available in minutes at the point of care. Accuracy of the AmniSure test is documented in multiple clinical studies and approaches 99% - far superior to traditional methods.

Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation. This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples. We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results.

Cellestis is manufactures and markets QuantiFERON products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses using whole blood samples.

Ipsogen is develops and markets diagnostic tests in the field of oncology worldwide. The company offers diagnostic kits and biomarkers. Its products are used in the diagnosis, prognosis, and monitoring of patients with leukemia.

ESE GmbH is a company that was acquired by Qiagen in 2010.

SABiosciences Corporation, established in 1998, is a privately held biotechnology company that focuses on advancing biological research in the post-genomic era. The company develops and commercializes a portfolio of real-time PCR-based assay panels that are designed to target specific diseases and biological pathways. By integrating hypothesis-driven and discovery-based research methodologies, SABiosciences aims to provide researchers with innovative tools that enhance the efficiency and effectiveness of their studies.

DxS (now a Qiagen company) is a personalized medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. Working in partnership with pharmaceutical companies, DxS will support the development and sales of targeted cancer therapies by providing companion diagnostic products and services. Since its founding in 2001, DxS has experienced considerable growth and firmly established itself as a leader in companion diagnostics, having recently secured deals with leading healthcare companies such as Amgen, Boehringer Ingelheim, and AstraZeneca. In addition, DxS has an exclusive agreement with Roche Diagnostics for the global distribution of its diagnostic products. DxS has a portfolio of cancer mutation products including both diagnostic and assays for research use. The TheraScreen® range of CE-marked (IVD) diagnostic* kits can identify genetic tumor mutations that affect how patients respond to cancer therapies, thus enabling doctors to provide the most beneficial treatment. DxS currently produce two diagnostic kits, TheraScreen K-RAS and TheraScreen EGFR29. The TheraScreen: K-RAS Mutation kit is a companion diagnostic for Vectibix® (Amgen) and Erbitux® (Merck KGaA) for the treatment of colorectal cancer. DxS was acquired by Qiagen (NASDQ : QGEN) and continues to operate from the heart of Manchester’s Technology Quarter in the UK.

Explera s.r.l. engages in importing, manufacturing, and marketing products in the molecular biology field for research laboratories in Italy and internationally. It offers instrumentations for DNA sequencing; thermal cyclers; ultra-compact thermal cycling products; photo-documentation systems; small equipments, such as shakers and rotators, multi shakers, shakers-incubators and thermo-shakers, centrifuges and vortexes, thermostats, water baths, dry blocks, and magnetic stirres; centrifuges; and biohazard and PCR cabinets.

Corbett Life Science Pty., Ltd. designs, manufactures, and distributes instrumentation systems for the life sciences sector on an international scale. The company is known for its innovative products, including the Rotor-Gene, a real-time PCR cycler, and a range of automation solutions such as the CAS-1200 PCR setup robot and precision liquid handling workstations like the CAS-4200 and CAS-4800. Additionally, Corbett offers the X-tractor Gene nucleic acid extraction system, the Palm-Cycler thermal cycler, and various reagents and software tools for DNA analysis. Its products facilitate critical processes like DNA amplification, extraction, and analysis, serving laboratories worldwide, including regions such as North America, Europe, and Asia. Founded in 1988 and headquartered in Sydney, Australia, Corbett Life Science operates additional units in Brisbane, the United Kingdom, and the United States. The company has a strategic partnership with Sigma-Aldrich and has been a subsidiary of Qiagen NV since 2008.

eGene, Inc. is a biotechnology company, engages in developing, manufacturing, and marketing analytical systems and reagents for the genotyping market. It uses capillary electrophoresis, microfluidics, reagents liquid handling, and automation technologies to create a DNA/RNA analysis system for biological materials and life sciences testing. The company offers HDA-GT12 genetic analyzer, which uses capillary electrophoresis-based technology for DNA/RNA separation. Its HDA-GT12 system is used to detect, quantify, identify, and characterize biological organisms, as well as to automate the routine and non-routine laboratory and industrial procedures.

Digene Corporation is develops, manufactures, and markets proprietary gene-based diagnostic tests for the screening, monitoring, and diagnosis of human diseases with a focus on women’s cancers and infectious diseases worldwide. The company primarily offers human papillomavirus (HPV) testing products, which are FDA-approved tests for the detection of HPV, are a reproducible, objective test for the primary cause of cervical cancer. Its primary product is The Digene HPV Test, a FDA-approved test for HPV, the primary cause of cervical cancer.

Genaco Biomedical Products, Inc. develops and markets medical genetic products and services in China. The company offers prenatal screening; neonatal screening; commercial kits for prenatal screening and diagnosis of common genetic diseases; cytogenetic equipment; molecular genetics equipment, such as gel boxes and power supplies; and general laboratory supplies. It distributes its products through distributors and medical genetic centers.

Gentra Systems, Inc. develops and markets nucleic acid purification reagents and instruments for clinical and clinical research laboratories. The company’s DNA and RNA purification products include Generation Kits, which provide DNA purification for small samples; Purescript kit that provides a non-toxic method for purifying RNA; Autopure ls instrument for processing samples, by purifying Puregene-quality DNA from blood samples; and Versagene RNA.

Shenzhen PG Biotech Co, Ltd., is a molecular biology company, engages in the development, manufacture, and marketing of research and clinic diagnosis reagents and instruments. Its integrated services include technical consultation, product introduction, and customer order upon request, as well as after-sale service. The company serves in the areas of scientific fields, including molecular biology, cell biology, genetics, microbiology, and management.

Nextal Biotechnologies, located in Holland, Ohio, focuses on producing screens and plates essential for protein crystallization, a critical component in structural biology and structure-based drug design. The company's products cater to the experimental requirements of crystallization by offering innovative plates that feature grease-free, independent screwable supports. As of January 2020, Nextal Biotechnologies operates as a subsidiary of CalibreScientific Inc.

Artus GmbH is a biotechnology company that specializes in the development, production, and sale of diagnostic kits utilizing advanced DNA analytical techniques. The company primarily focuses on polymerase chain reaction (PCR) and real-time PCR technologies to detect infectious agents. Its diagnostic kits are employed across various fields, including pharmacogenomics and veterinary diagnostics, helping users achieve more accurate and effective diagnoses.

Molecular Staging, Inc. is a life sciences tool company focused on developing technologies for the detection and measurement of proteins and nucleic acids. Its offerings encompass various applications in proteomics, genomics, pharmacogenomics, and diagnostics. Notable products include protein microarrays, which allow researchers to analyze multiple proteins simultaneously, and whole-genome amplification technology that addresses challenges posed by limited DNA sample quantities. Additionally, the company provides multiplexed diagnostics, facilitating the earlier detection of diseases and enhancing confirmatory diagnoses. Through these innovations, Molecular Staging supports advancements in research and clinical applications.

Xeragon is develops and markets products and services focusing on oligoribonucleotides (RNA). The company’s TOM-Amidite technology allows chemical synthesis of RNA and its siRNA technology helps in RNA synthesis and gene silencing. Xeragon’s products and services are used by RNA scientists in the fields of biopharmaceuticals, diagnostics, therapeutics, and structural studies.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.

Genoox, Ltd. is a company that develops a cloud-based platform for managing and analyzing genomic data. Founded in 2014, the company aims to create a comprehensive network of real-world genomic and clinical data to enhance genetic diagnostics and personalized treatments. The platform connects clinicians, genetic counselors, and healthcare organizations, allowing them to share insights and make significant discoveries using advanced genomic tools and applications. By leveraging artificial intelligence and machine learning, Genoox's platform translates complex genetic data into actionable clinical information, helping healthcare providers to analyze rare genetic mutations and improve patient outcomes with increased accuracy and efficiency. The company is headquartered in Israel and serves over 1,700 health organizations across 44 markets worldwide.